SCPC Responds to CMS Proposed Part D Rule
Prioritize Independent Metrics for Prescription Drug Plans (PDPs) to Determine Long-Term Care (LTC) Pharmacy Payments and Appropriate Implementation of Opioid Crisis Response
Washington, DC – Commenting today on a recently-released Centers for Medicare and Medicaid Services (CMS) Proposed Rule regarding regulatory changes to key Medicare Part D provisions, the Senior Care Pharmacy Coalition (SCPC) offered policy recommendations.
President and CEO of SCPC, Alan G. Rosenbloom, pointed to two key recommendations as organization priorities requiring proper CMS implementation:
First, quality metrics that prescription drug plans (PDPs) use to evaluate and compensate long-term care (LTC) pharmacies must be developed independently. These metrics should be relevant to better outcomes for the LTC patient population and only evaluate practices within the control of LTC pharmacies that are relevant to the LTC patient population and within the control of LTC pharmacies. Rosenbloom says SCPC “strongly supports full disclosure, including public disclosure of quality measures PDPs use to evaluate and adjust payments to LTC pharmacies.”
Second, CMS must implement recent legislation Congress enacted in response to the opioid crisis as intended with respect to Part D beneficiaries living in nursing homes and other LTC facilities and settings.
Additionally, he continued, “SCPC urges CMS to add criteria PDPs must use before adopting pharmacy quality measures, including appropriate processes for metric development, independent validation of metrics, reasonable relationship between metrics and improved patient outcomes, use of metrics concerning practices within control of the pharmacy; use of metrics unrelated to financial performance of PDPs, PBMs or any pharmacies with corporate affiliations with PDPs, PBMs or any shared corporate parents, consistent application of metrics across all PDPs and metrics demonstrably relevant to the LTC patient population.”
Regarding opioid management provisions included in the Comprehensive Addiction and Recovery Act of 2016 and the within the SUPPORT for Patients and Communities Act of 2018, Rosenbloom stated: “We applaud Congressional and agency efforts to reduce and control prescription drug abuse in the Medicare Part D program. We further commend the agency for striking the appropriate balance in the Proposed Rule between this objective and the very low risk of prescription drug abuse among Part D beneficiaries residing in LTC facilities and other congregate and residential care settings.” He noted, however, that SCPC “emphasizes the need to implement fully the statutory provisions designed to exempt Part D beneficiaries in LTC facilities from certain opioid management requirements.”
The Senior Care Pharmacy Coalition (SCPC) is the only national organization exclusively representing the interests of LTC pharmacies. Its members operate in all 50 states and serve 850,000 patients daily in skilled nursing and assisted living facilities across the country. Visit seniorcarepharmacies.org to learn more.
Senior Care Pharmacy Coalition Applauds Chairman Comer and House Oversight Committee for Shedding Light on Harmful PBM Practices, Encourages Congress to Advance PBM Reform Legislation Heard Today in House Energy and Commerce Committee Health Subcommittee
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy community, released a statement today regarding the House Oversight Committee’s hearing on pharmacy benefit managers.
Stuck in the middle, LTC pharmacies could be dangerously squeezed by drug price negotiations
Any lower drug prices that result from White House efforts to negotiate on behalf of Medicare beneficiaries may lead to short-term gains for nursing homes, but there also could be a steep price to pay in the long-term, experts warned this week. The Centers for Medicare & Medicaid Services on Tuesday announced the first 10 drugs covered by Medicare Part D that will be included in negotiations running through 2024. They are all commonly prescribed drugs that treat conditions ranging from diabetes to arthritis and heart failure.
Biden’s Plans to Reduce Cost of Medicare Drugs To Send Ripple Effects Through Nursing Home Industry
Following the Biden Administration’s bid this week to reduce the price of certain drugs – many of which are commonly used in nursing homes – experts are cautioning that the changes may negatively impact the bottomline of organizations in the sector. As Medicare Part D price negotiations for these drugs come into focus this week, the Senior Care Pharmacy Coalition (SCPC), for one, is warning that changes to Part D might cause “collateral damage” to long-term care pharmacies, the patients they serve and operator partners.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.